Excerpt from:
Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan
Category Archives: Global News Feed
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Originally posted here:
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
View original post here:
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
Read the original here:
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
AccuStem Announces Adjournment of Annual Meeting of Stockholders
PacBio Grants Equity Incentive Award to New Employee
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types…
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
Genmab Announces Initiation of Share Buy-Back Program
Continued here:
Genmab Announces Initiation of Share Buy-Back Program
Interim report for Q1 2022
View post:
Interim report for Q1 2022